FullHope Biomedical Co (ROCO:7773) EBIT: NT$-38.61 Mil (TTM As of Dec. 2025)


ROCO:7773 FullHope Biomedical Co Ltd ROCO:7773
14 GF Score
Price NT$27.65
! 1 Warning Sign
View Full Analysis

What is FullHope Biomedical Co EBIT?

FullHope Biomedical Co ROCO:7773 14 EBIT is NT$-38.61 Mil as of Dec. 2025. GuruFocus rates ROCO:7773 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

FullHope Biomedical Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$-17.65 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-38.61 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. FullHope Biomedical Co's annualized ROC % for the quarter that ended in Dec. 2025 was -32.20%. FullHope Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -117.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. FullHope Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -4.95%.

FullHope Biomedical Co  (ROCO:7773) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

FullHope Biomedical Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-44.44 * ( 1 - 0% )/( (40.761 + 235.295)/ 2 )
=-44.44/138.028
=-32.20 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=587.857 - 7.887 - ( 541.293 - max(0, 15.301 - 554.51+541.293))
=40.761

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=571.447 - 10.079 - ( 331.23 - max(0, 17.229 - 343.302+331.23))
=235.295

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

FullHope Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-35.304/( ( (31.284 + max(2.3109999999999, 0)) + (26.708 + max(-0.67200000000001, 0)) )/ 2 )
=-35.304/( ( 33.595 + 26.708 )/ 2 )
=-35.304/30.1515
=-117.09 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.222 + 7.429 + 4.5549999999999) - (7.887 + 0 + 3.008)
=2.3109999999999

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.95 + 5.393 + 3.729) - (10.079 + 0 + 2.665)
=-0.67200000000001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

FullHope Biomedical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-38.606/779.880
=-4.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FullHope Biomedical Co EBIT Related Terms

FullHope Biomedical Co EBIT Historical Data

* Premium members only.

The historical data trend for FullHope Biomedical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FullHope Biomedical Co EBIT Chart

FullHope Biomedical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
0.00 -43.55 -41.63 -55.74 -38.61

FullHope Biomedical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial -25.26 -23.68 -32.06 -20.95 -17.65

ROCO:7773 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, FullHope Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FullHope Biomedical Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FullHope Biomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where FullHope Biomedical Co's EV-to-EBIT falls into.


ROCO:7773
14GF Score
FullHope Biomedical Co Ltd ROCO:7773
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

FullHope Biomedical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-38.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-38.61 Mil mean?
FullHope Biomedical Co (ROCO:7773) has a EBIT of NT$-38.61 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on FullHope Biomedical Co.
Is FullHope Biomedical Co's EBIT too high?
FullHope Biomedical Co's current EBIT is NT$-38.61 Mil. Overall, FullHope Biomedical Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does FullHope Biomedical Co's EBIT compare to VRTX and REGN?
FullHope Biomedical Co's EBIT of NT$-38.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on FullHope Biomedical Co. FullHope Biomedical Co's current EBIT is NT$-38.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FullHope Biomedical Co stock overvalued right now?
FullHope Biomedical Co (ROCO:7773) has a current EBIT of NT$-38.61 Mil. The current EBIT is NT$-38.61 Mil. FullHope Biomedical Co's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For FullHope Biomedical Co (ROCO:7773), the current EBIT is NT$-38.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FullHope Biomedical Co Business Description

Address Lane 609, Sector. 5, Chongxin Road, 10th Floor, No. 10, Sanchong District, New Taipei City, TWN
FullHope Biomedical Co Ltd focuses on immune system-related services and innovative R&D. It establishes cell-based immunotherapies for cancers and autoimmune disorders. Its services are, Immunoprofiling, Circulating Tumor Cells Testing, Regulation of Cell Therapy, Contracting Immune Cell Manufacturing, Immune Cell Bank, Contract Research Organization, and Endotoxin and Mycoplasma Detection Service.
14GF Score

Get the complete analysis for ROCO:7773

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.65
Price